1. HGF/c‐MET pathway contributes to cisplatin‐mediated PD‐L1 expression in hepatocellular carcinoma
- Author
-
Yuan-Yuan Dou, Meng-Wen Hu, Juan Guo, Ruo-Han Yang, Dong Fang, Yue-Ying Cheng, Zi-Xuan Gao, Hui Zhao, De-Fei Qi, Wen-Ke Zhang, Chao-Yan Yao, Hong-Xiang Shi, Zhan-Sheng Zhang, and Xin Yao
- Subjects
Male ,MAPK/ERK pathway ,Programmed cell death ,Carcinoma, Hepatocellular ,C-Met ,MAP Kinase Signaling System ,CD8-Positive T-Lymphocytes ,B7-H1 Antigen ,Mice ,Phosphatidylinositol 3-Kinases ,chemistry.chemical_compound ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Cisplatin ,Mice, Inbred BALB C ,Hepatocyte Growth Factor ,Chemistry ,Liver Neoplasms ,Cell Biology ,General Medicine ,Proto-Oncogene Proteins c-met ,Cancer cell ,Cancer research ,Hepatocyte growth factor ,Proto-Oncogene Proteins c-akt ,Signal Transduction ,medicine.drug - Abstract
Cisplatin has been reported to promote the expression of programmed cell death ligand-1 (PD-L1) in some cancer cells. However, the underlying mechanism through which PD-L1 is transcriptionally regulated by cisplatin in hepatocellular carcinoma (HCC) cells remains largely unknown. In the present study, we found that the expression of hepatocyte growth factor (HGF), p-Akt, p-ERK, and PD-L1 was increased in cisplatin-treated SNU-368 and SNU-739 cells. HGF stimulation also increased PD-L1 expression in these cells. Moreover, Inhibition of HGF/c-MET, PI3K/Akt, and MEK/ERK signaling pathways can dramatically block cisplatin or HGF-induced PD-L1 expression in SNU-368 and SNU-739 cells. In vivo, combination PHA665752 with cisplatin significantly reduced tumor weight with increased infiltration of CD8+ T cells in the tumor. Taken together, our study suggested that HGF/c-Met axis-induced the activation of PI3K/Akt and MEK/ERK pathways contributes to cisplatin-mediated PD-L1 expression. These findings may provide an alternative avenue for the treatment of HCC.
- Published
- 2021
- Full Text
- View/download PDF